Blackstone commits up to $1.5B for R&D of Pfizer's ex-Metsera GLP-1

Pfizer has secured up to $1.5 billion from the investment group Blackstone Life Sciences to help pay for the development of its obesity candidate berobenatide. The co-funding agreement will see that cash come from funds ...